Pros | - | ![]() 5Y returns in the top 25% of the category. ![]() 3Y returns in the top 25% of the category. ![]() Beats FD returns for both 3Y & 5Y duration. | ||
Cons | - | - |
INDMoney rank | - | 1/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 3 Years | 12 Years | ||
Fund Size | 214 Cr | 3313 Cr | ||
Min Investment | SIP ₹500 Lumpsum ₹5000 | SIP ₹500 Lumpsum ₹5000 | ||
Expense Ratio | 0.47% | 0.97% | ||
Exit Load | 1% | 0.5% | ||
Benchmark Index | Nifty Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 41 | 32 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (15.86%) Lupin Ltd (6.26%) Suven Pharmaceuticals Ltd (6.06%) Divi's Laboratories Ltd (5.67%) Apollo Hospitals Enterprise Ltd (5.02%) | Sun Pharmaceuticals Industries Ltd (13.47%) Max Healthcare Institute Ltd Ordinary Shares (6.5%) Divi's Laboratories Ltd (6.2%) Cipla Ltd (5.1%) Lonza Group Ltd ADR (5%) | ||
No of Sectors | 3 | 3 | ||
Top 3 Sectors | Health (95.55%) Basic Materials (3.41%) Industrial (1.04%) | Health (92.92%) Basic Materials (7.08%) Government (3.05%) | ||
Equity % | 97.86% | 97.29% | ||
Debt % | - | 0.09% | ||
P/E | 37.64 | 42.28 | ||
P/B | 5.87 | 5.85 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 2.25% | 1.95% | ||
3-Month Return | -8.66% | -5.91% | ||
6-Month Return | -9.86% | -4.33% | ||
1-Year Return | 11.93% | 16.11% | ||
3-Year Return | 18.45% | 22.58% | ||
5-Year Return | - | 25.91% |
Sharpe | 0.84 | 1.12 | ||
Alpha | 2.89 | 5.03 | ||
Beta | 0.91 | 0.85 | ||
Standard Deviation | 16.41 | 14.93 | ||
Information Ratio | 0.51 | 1 |
Description | ITI Pharma and Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | SBI Healthcare Opportunities Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | - | Tanmaya Desai |